Screener
Kyverna Therapeutics, Inc. KYTX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $257,024 | $293,826 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $11,603 | $5,306 |
| Accrued compensation | 3,114 | 9,990 |
| Accrued license expense – related party | 3,750 | 3,750 |
| Other accrued expenses and current liabilities | 9,222 | 13,472 |
| Operating lease liabilities, short-term portion | 1,764 | 3,662 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s accounts payable?
- Kyverna Therapeutics, Inc. (KYTX) reported accounts payable of $11.6M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s accounts payable changed year-over-year?
- Kyverna Therapeutics, Inc.'s accounts payable increased by 37.0% year-over-year, from $8.47M to $11.6M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s accounts payable?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s accounts payable has grown at a 121.1% compound annual growth rate (CAGR), from $5.46M to $26.71M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Kyverna Therapeutics, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude